Helix Biopharma Corp. HBP.TO
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 65.03% | 57.97% | 49.31% | 45.19% | -51.20% |
| Total Depreciation and Amortization | -67.44% | -47.87% | -45.10% | -30.39% | -21.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -96.43% | -94.15% | -90.46% | -99.34% | 623.67% |
| Change in Net Operating Assets | -99.64% | -89.89% | -80.90% | 176.66% | 708.08% |
| Cash from Operations | 17.77% | 0.52% | 4.06% | 28.85% | 36.90% |
| Capital Expenditure | 100.00% | 100.00% | 6.67% | 86.41% | 69.79% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | 30.51% | -- | 267.57% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | -100.00% | 43.18% | 218.45% | 284.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 36.79% | -68.19% | 57.94% | -49.16% | -28.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 39.47% | -68.40% | 52.67% | -51.37% | -30.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | 350.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14,213.64% | -205.59% | 117.38% | -492.21% | 97.66% |